癌症高甲基化1在非小细胞肺癌中的表达及其临床意义

doi:10.11904/j.issn.1002-3070.2024.05.005

Abstract

Abstract: Objective The aim of this study was to investigate the correlation between the expression of hypermethylated in cancer 1(HIC1)and overall survival(OS)in non-small cell lung cancer(NSCLC)patients. Methods A total of 2,166 patients with NSCLC,including 1 161 patients with adenocarcinoma and 780 patients with squamous cell carcinoma,were collected from the Kaplan-Meier plotter plus(KM plotter)database with detailed pathological type,clinical stage,treatment information,and complete RNA-seq or Gene chip data.Univariate Cox proportional risk regression analysis was performed using KM plotter online database.Multivariate Cox regression analysis corrected for the following confounding factors:gender,smoking history,clinical stage,surgical margin status,chemotherapy and radiotherapy.The relationship between the expression of HIC1 mRNA and OS in 2,166 NSCLC patients was analyzed.Transwell migration assay was used to detect the effect of knockdown HIC1 gene on the migration ability of PC9 cells(lung adenocarcinoma cell line). Results In lung adenocarcinoma patients receiving chemotherapy,the high expression of HIC1 significantly prolonged the OS(HR=0.54,95% CI:0.34-0.86,P=0.009),and reduced the risk of death by 46%.Transwell cell migration assay showed that the migration ability in PC9 cells in the low expression of HIC1 was increased(P＜0.001). Conclusion The expression of HIC1 mRNA may be an important prognostic predictor for NSCLC patients receiving chemotherapy.

Key words: Non-small cell lung cancer, Hypermethylated in cancer 1, Overall survival

CLC Number:

R734.2

HAO Huiting, ZHAO Huijuan, XU Qiaohui. Expression and clinical significance of hypermethylated in cancer 1 in non-small cell lung cancer[J]. Journal of Practical Oncology, 2024, 38(5): 306-312.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2024.05.005

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2024/V38/I5/306

References

1 Siegel RL,Miller KD,Fuchs HE,et al.Cancer statistics,2022[J].CA Cancer J Clin,2022,72(1):7-33.
2 Han BF,Zheng RS,Zeng HM,et al.Cancer incidence and mortality in china,2022[J].J Natl Cancer Cent,2024,(1):47-53.
3 Herbst R,Heymach,J,Lippman S.Lung cancer[J].N Engl J Med,2008,359(13):1367-1380.
4 Wales M,Biel M,Deiry M,et al.p53 activates expression of HIC-1,a new candidate tumor suppressor gene on 17p13.3[J].Nat Med,1995,1(6):570-577.
5 Van Rechem C,Boulay G,Pinte S,et al.Differential regulation of HIC1 target genes by CtBP and NuRD,via an acetylation/SUMOylation switch,in quiescent versus proliferating cells[J].Mol Cell Biol,2010,30(16):4045-4059.
6 Chen WY,Wang DH,Yen RC,et al.Baylin,tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses[J].Cell,2005,123(3):437-448.
7 Wang X,Wang Y,Xiao G,et al.Hypermethylated in cancer 1(HIC1)suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway[J].Oncotarget,2016,7(21):30350-30364.
8 Zhou XG,Zhang P,Hu H,et al.Hypermethylated in cancer 1(HIC1)suppresses bladder cancer progression by targeting yes-associated protein(YAP)pathway[J].J Cell Biochem,2019,120(4):6471-6481.
9 Yinli Z,Leyan L,Haipeng C,et al.Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression[J].Free Radic Biol Med,2023,1:208:530-544.
10 Carter M,Johns M,Zeng X,et al.Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome[J].Hum Mol Genet,2000,9(3):413-419.
11 Chen WY,Zeng,Carter X,et al.Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors[J].Nat Genet,2003,33(2):197-202.
12 Zheng J,Wang J,Sun X,et al.HIC1 modulates prostate cancer progression by epigenetic modification[J].Clin Cancer Res,2013,19(6):1400-1410.
13 Hao M,Y.Li Y,Wang J,et al.HIC1 loss promotes prostate cancer metastasis by triggering epithelial-mesenchymal transition[J].J Pathol,2017,242(4):409-420.
14 Paget S,Dubuissez M,Dehennaut V,et al.HIC1(hypermethylated in cancer 1)SUMOylation is dispensable for DNA repair but is essential for the apoptotic DNA damage response(DDR)to irreparable DNA double-strand breaks(DSBs)[J].Oncotarget,2017,8(2):2916-2935.
15 Yu J,Liu P,Cui X,et al.Identification of novel subregions of LOH in gastric cancer and analysis of the HIC1 and TOB1 tumor suppressor genes in these subregions[J].MOL CELLS,2011,32(1):47-55.
16 Lánczky A,Nagy Á,Bottai G,et al.miRpower:a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients[J].Breast Cancer Res Treat,2016,160:439-446.
17 Györffy B,Surowiak P,Budczies J,et al.Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer[J].PLoS One,2013,8:e82241.
18 Wang J,Ye C,Lu D,et al.Matrix metalloproteinase-1 expression in breast carcinoma:a marker for unfavorable prognosis[J].Oncotarget,2017,8:91379-91390.
19 Liang YK,Lin HY,Chen CF,et al.Prognostic values of distinct CBX family members in breast cancer[J].Oncotarget,2017,8:92375-92387.
20 Fang E,Zhang X.Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis[J].Cancer Biomark,2017,21(1):373-381.
21 Xie L,Li T,Yang LH.E2F2 induces MCM4,CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival[J].Eur Rev Med Pharmacol Sci,2017,21:2150-2156.
22 Zhang X,Wang W,Li P,et al.High TREM2 expression correlates with poor prognosis in gastric cancer[J].Hum Pathol,2018,72:91-99.
23 Xiong J,Zhang X,Chen X,et al.Prognostic roles of mRNA expression of notch receptors in non-small cell lung cancer[J].Oncotarget,2017,8:13157-13165.
24 Huang ZC,Li H,Sun ZQ,et al.Distinct prognostic roles of HSPB1 expression in non-small cell lung cancer[J].Neoplasma,2018,65:161-166.
25 Janeckova L,Kolar M,Svec J,et al.HIC1 expression distinguishes intestinal carcinomas sensitive to chemotherapy[J].Transl Oncol,2016,9:99-107.
26 Rood BR,Zhang H,Weitman DM,et al.Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma[J].Cancer Res,2002,62(13):3794-3797.
27 Gu XY,Huang XT,Zhang XX,et al.Development and validation of a DNA methylation-related classifier of circulating tumour cells to predict prognosis and to provide a therapeutic strategy in lung adenocarcinoma[J].Int J Biol Sci,2022,18(13):4984-5000.
28 Yanlin W,Zhengjun L,Xianzhe T,et al.Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity[J].Front Immunol,2023,14:1182030.
29 Yue L,Mengfei Y,Tianqi W,et al.Loss of hypermethylated in cancer 1(HIC1)promotes lung cancer progression[J].Cell Signal,2019,53:162-169.

[1]	XU Lingyan, LI Qianni, LI Jian, YAO Xuepei, LIU Meina. Analysis for the impact of the first hospitalization days on treatment quality in patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(4): 221-226.
[2]	YAO Xuepei, BAI Shanqi, LIU Meina. Analysis of factors influencing treatment quality of non-small cell lung cancer based on causal diagram model [J]. Journal of Practical Oncology, 2024, 38(4): 227-234.
[3]	LI Jian, LI Qianni, XU Lingyan, YAO Xuepei, LIU Meina. Research on the causal effects of non-small cell lung cancer treatment process on in-hospital mortality based on double robust estimation method [J]. Journal of Practical Oncology, 2024, 38(4): 235-240.
[4]	CHENG Yongming, DONG Huanhuan, XU Hui. Hsa-let-7b-5p inhibits proliferation,migration and invasion in non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(3): 157-167.
[5]	ZHANG Xuan, LI Xin, ZHAO Kang. Relationship between serum inflammatory markers and prognosis of advanced non-small cell lung cancer patients treated with first-line immunosuppressants [J]. Journal of Practical Oncology, 2024, 38(1): 37-44.
[6]	MIAO Ling, ZHAO Zhihan, WANG Min. Levels and clinical significance of PA28γ and miR-7-5p in tumor tissues of patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 344-350.
[7]	CAO Yingyue, PANG Luyi, ZHANG Jian, JIN Shi. The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 383-388.
[8]	CHEN Qi, HE Mingxv, JIA Keliang, MIAO Jianlong, HAN Liping. Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation [J]. Journal of Practical Oncology, 2023, 37(3): 262-266.
[9]	LONG Chaolian, LI Kun, LIU Zichen, ZHANG Nana, CHE Nanying. The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation [J]. Journal of Practical Oncology, 2023, 37(2): 117-122.
[10]	XU Zihan, YU Guohua, NIE Yuhui, SUN Mengmeng, FENG Hui, LIU Shuzhen. Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome [J]. Journal of Practical Oncology, 2022, 36(6): 544-550.
[11]	ZHU Kaibin, HE Changjun, CHEN Lantao, KONG Xianglong, ZHAO Su, XU Shidong. Tumor-associated macrophages promotes non-small cell lung cancer growth and tumor vascularization via PLGF/Flt-1 and TGF-β1 signal pathway [J]. Journal of Practical Oncology, 2022, 36(5): 391-397.
[12]	LIU Qianqian, SHANG Lihua. Research progress on the correlation between immune-related adverse reactions and efficacy of immunotherapy in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(5): 463-467.
[13]	DONG Lin, LIU Xin, LU Hailing. Research progress of anti-angiogenic therapy combined with immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2022, 36(4): 351-355.
[14]	ZHANG Hao, YANG Xinguan, HE Yong. Analysis of the correlation between sarcopenia and the clinicopathological characteristics and prognosis of advanced NSCLC [J]. Journal of Practical Oncology, 2022, 36(3): 214-219.
[15]	ZHANG Yiyi, LI Qi, LIU Xu, WANG Yanan, ZOU Yuanjie, ZHOU Huihui, XU Chunyan, SU Shengqi, GE Xin, WANG Tong. Analysis of 5-year survival and its influencing factors of patients with cervical cancer [J]. Journal of Practical Oncology, 2022, 36(1): 7-13.

Expression and clinical significance of hypermethylated in cancer 1 in non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments